Month: May 2020

CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition...

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx®  test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza® (olaparib). Lynparza is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Lynparza is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE:...

ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2020 at 2:00 p.m. ET.The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair....

CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Bernstein 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available following the event for 90 days.About BeiGeneBeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access...

F-Secure Corporation, Stock Exchange Release, 20 May 2020, at 14.00 EESTF-Secure Corporation – Managers’ Transactions – Risto SiilasmaaF-Secure Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Siilasmaa, RistoPosition: Member of the Board/Deputy memberIssuer: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20200514130205_3____________________________________________Transaction date: 2020-05-19Venue not applicableInstrument type: SHAREISIN: FI0009801310Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATIONTransaction details(1): Volume: 11,510 Unit price: 0 EURAggregated transactions(1): Volume: 11,510 Volume weighted average price: 0 EURContact...

F-Secure Oyj, Pörssitiedote, 20.5.2020 klo 14.00F-Secure Oyj – Johdon liiketoimet – Risto SiilasmaaF-Secure Oyj – Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Siilasmaa, RistoAsema: Hallituksen jäsen/varajäsenLiikkeeseenlaskija: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700ATXLT0MFCHXT16_20200514130205_3____________________________________________Liiketoimen päivämäärä: 2020-05-19Kauppapaikka ei sovelluInstrumenttityyppi: OSAKEISIN: FI0009801310Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINENLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 11 510 Yksikköhinta: 0 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 11 510 Keskihinta: 0 EURLisätietoja:Tiina Sarhimaa, Lakiasiainjohtaja, F-Secure Oyj+358 50 561 0080investor-relation...

YAVNE, Israel, May 20, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the first quarter ended March 31, 2020 and provided business and financial updates related to the COVID-19 pandemic. First Quarter Business and Financial Highlights:Total revenues for the first quarter of 2020 were $4.4 million Operating loss for the first quarter of 2020 was $2.2 million, representing a 38% decrease compared to prior-year period Operating cash flow was $2.1 million, and as of March 31, 2020, the company had $27.3 million in cash and short-term investments Subsequent to the end of the quarter, the Company resumed patient screening and randomization in...

F-Secure Corporation, Stock Exchange Release, 20 May 2020, at 14.00 EESTF-Secure Corporation – Managers’ Transactions – Pertti ErviF-Secure Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Ervi, PerttiPosition: Member of the Board/Deputy memberIssuer: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20200514130854_3____________________________________________Transaction date: 2020-05-19Venue not applicableInstrument type: SHAREISIN: FI0009801310Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATIONTransaction details(1): Volume: 6,906 Unit price: 0 EURAggregated transactions(1): Volume: 6,906 Volume weighted average price: 0 EURContact information:Tiina...

F-Secure Oyj, Pörssitiedote, 20.5.2020 klo 14.00F-Secure Oyj – Johdon liiketoimet – Pertti ErviF-Secure Oyj – Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Ervi, PerttiAsema: Hallituksen jäsen/varajäsenLiikkeeseenlaskija: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700ATXLT0MFCHXT16_20200514130854_3____________________________________________Liiketoimen päivämäärä: 2020-05-19Kauppapaikka ei sovelluInstrumenttityyppi: OSAKEISIN: FI0009801310Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINENLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 6 906 Yksikköhinta: 0 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 6 906 Keskihinta: 0 EURLisätietoja:Tiina Sarhimaa, Lakiasiainjohtaja, F-Secure Oyj+358 50 561 0080investor-relations@f-secure...

 –  Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile –GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of positive preclinical data that provide the foundation for the vector and starting dose used in its ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene. The data, which demonstrate that the company’s proprietary AAV vector and engineered...